Literature DB >> 24224849

Substance use in clinical high risk for psychosis: a review of the literature.

Jean Addington1, Nevicia Case, Majid M Saleem, Andrea M Auther, Barbara A Cornblatt, Kristin S Cadenhead.   

Abstract

AIM: In the literature, there is evidence suggesting an association between substance use and psychosis. However, little is known about substance use in those who may be in the pre-psychotic phase, that is, those who are putatively prodromal are considered to be at clinical high risk (CHR) of developing psychosis.
METHODS: We conducted a review of publications measuring patterns and rates of substance use in CHR for psychosis individuals and the effects on the transition to psychosis.
RESULTS: Of 5527 potentially relevant research papers, 10 met inclusion criteria of CHR subjects and specifically mentioned substance use in the sample. The results of these studies varied. Cannabis, alcohol and tobacco/nicotine were reported as the most commonly used substances. There was limited information on the changes in patterns of use over time. Two out of the ten studies found a significant association between the use of substances and subsequent transition to psychosis. In one of these studies, substance abuse was a predictor of psychosis when included as a variable in a prediction algorithm. In the other study, the abuse of cannabis and nicotine was associated with transition to psychosis.
CONCLUSIONS: We found limited evidence to suggest that increased rates of substance use may be associated with transition to psychosis. However, further prospective research examining the association between substance use and transition to psychosis is required before any firm conclusions can be made.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  cannabis; clinical high risk; psychosis; review; substance use

Mesh:

Year:  2013        PMID: 24224849      PMCID: PMC4356483          DOI: 10.1111/eip.12100

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  56 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

2.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Authors:  Stanley Zammit; Peter Allebeck; Sven Andreasson; Ingvar Lundberg; Glyn Lewis
Journal:  BMJ       Date:  2002-11-23

Review 3.  SCAN. Schedules for Clinical Assessment in Neuropsychiatry.

Authors:  J K Wing; T Babor; T Brugha; J Burke; J E Cooper; R Giel; A Jablenski; D Regier; N Sartorius
Journal:  Arch Gen Psychiatry       Date:  1990-06

4.  Cannabis and schizophrenia.

Authors:  S Andréasson; P Allebeck; A Engström; U Rydberg
Journal:  Lancet       Date:  1988-04-30       Impact factor: 79.321

5.  Comorbidity in psychosis at first hospitalization.

Authors:  S M Strakowski; M Tohen; A L Stoll; G L Faedda; P V Mayer; M L Kolbrener; D C Goodwin
Journal:  Am J Psychiatry       Date:  1993-05       Impact factor: 18.112

6.  Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders.

Authors:  T W Haywood; H M Kravitz; L S Grossman; J L Cavanaugh; J M Davis; D A Lewis
Journal:  Am J Psychiatry       Date:  1995-06       Impact factor: 18.112

7.  Medication noncompliance and substance abuse among patients with schizophrenia.

Authors:  R R Owen; E P Fischer; B M Booth; B J Cuffel
Journal:  Psychiatr Serv       Date:  1996-08       Impact factor: 3.084

8.  Substance abuse in schizophrenia: service utilization and costs.

Authors:  S J Bartels; G B Teague; R E Drake; R E Clark; P W Bush; D L Noordsy
Journal:  J Nerv Ment Dis       Date:  1993-04       Impact factor: 2.254

9.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative.

Authors:  J I Nurnberger; M C Blehar; C A Kaufmann; C York-Cooler; S G Simpson; J Harkavy-Friedman; J B Severe; D Malaspina; T Reich
Journal:  Arch Gen Psychiatry       Date:  1994-11

Review 10.  Causal association between cannabis and psychosis: examination of the evidence.

Authors:  Louise Arseneault; Mary Cannon; John Witton; Robin M Murray
Journal:  Br J Psychiatry       Date:  2004-02       Impact factor: 9.319

View more
  25 in total

Review 1.  Is prevention a realistic goal for schizophrenia?

Authors:  Christian Kohler; Karin E Borgmann-Winter; Irene Hurford; Eli Neustadter; James Yi; Monica E Calkins
Journal:  Curr Psychiatry Rep       Date:  2014-04       Impact factor: 5.285

Review 2.  Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review.

Authors:  Megan S Farris; Mohammed K Shakeel; Jean Addington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-12-03       Impact factor: 4.328

3.  A critique of the "ultra-high risk" and "transition" paradigm.

Authors:  Jim van Os; Sinan Guloksuz
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

4.  Self-reported cannabis use is inconsistent with the results from drug-screening in youth at ultra high-risk for psychosis in Colorado.

Authors:  Emily E Carol; Vijay A Mittal
Journal:  Schizophr Res       Date:  2014-06-09       Impact factor: 4.939

5.  The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.

Authors:  Emily E Carol; Robert L Spencer; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2017-05-30       Impact factor: 4.905

6.  Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis.

Authors:  Lisa Buchy; Larry J Seidman; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; William Stone; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel H Mathalon; Jean Addington
Journal:  Psychiatry Res       Date:  2015-11-25       Impact factor: 3.222

7.  Early Detection of Psychosis: Recent Updates from Clinical High-Risk Research.

Authors:  Ariel Schvarcz; Carrie E Bearden
Journal:  Curr Behav Neurosci Rep       Date:  2015-01-18

8.  The psychosis spectrum in a young U.S. community sample: findings from the Philadelphia Neurodevelopmental Cohort.

Authors:  Monica E Calkins; Tyler M Moore; Kathleen R Merikangas; Marcy Burstein; Theodore D Satterthwaite; Warren B Bilker; Kosha Ruparel; Rosetta Chiavacci; Daniel H Wolf; Frank Mentch; Haijun Qiu; John J Connolly; Patrick A Sleiman; Hakon Hakonarson; Ruben C Gur; Raquel E Gur
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

9.  What prevents youth at clinical high risk for psychosis from engaging in physical activity? An examination of the barriers to physical activity.

Authors:  Raeana E Newberry; Derek J Dean; Madison D Sayyah; Vijay A Mittal
Journal:  Schizophr Res       Date:  2018-06-13       Impact factor: 4.939

Review 10.  Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians.

Authors:  Kristen A Woodberry; Daniel I Shapiro; Caitlin Bryant; Larry J Seidman
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.